Telix Financial Statements From 2010 to 2026

TLX Stock   7.62  0.13  1.74%   
Telix Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Telix Pharmaceuticals' valuation are provided below:
Gross Profit
358.3 M
Profit Margin
0.0163
Market Capitalization
3.3 B
Enterprise Value Revenue
4.3123
Revenue
664.2 M
We have found one hundred twenty available fundamental trend indicators for Telix Pharmaceuticals Limited, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Telix Pharmaceuticals Limited current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 124.2 M in 2026. Enterprise Value is likely to rise to about 101.4 M in 2026

Telix Pharmaceuticals Total Revenue

945.72 Million

Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Other Operating Expenses of 846.6 M, Operating Income of 77.6 M or EBITDA of 92.8 M, as well as many indicators such as Price To Sales Ratio of 11.37, Dividend Yield of 0.53 or PTB Ratio of 12.27. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Telix Stock
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Telix Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding416.8 M397 M186.2 M
Slightly volatile
Total Assets1.8 B1.7 B374.2 M
Slightly volatile
Total Current Liabilities399.6 M380.5 M88.8 M
Slightly volatile
Property Plant And Equipment Net65.6 M62.5 M15.5 M
Slightly volatile
Accounts Payable83 M79 M18.8 M
Slightly volatile
Cash857.7 M816.9 M167.7 M
Slightly volatile
Non Current Assets Total721.9 M687.5 M150.2 M
Slightly volatile
Cash And Short Term Investments857.7 M816.9 M165.5 M
Slightly volatile
Net Receivables192 M182.8 M42.4 M
Slightly volatile
Liabilities And Stockholders Equity1.8 B1.7 B373.9 M
Slightly volatile
Non Current Liabilities Total745.4 M709.9 M144.7 M
Slightly volatile
Total Liabilities1.1 B1.1 B233.3 M
Slightly volatile
Total Current Assets1.1 B1.1 B224.4 M
Slightly volatile
Short and Long Term Debt Total702.1 M668.7 M118.5 M
Slightly volatile
Good Will128.8 M122.6 M23 M
Slightly volatile
Inventory46.1 M43.9 M10.3 M
Slightly volatile
Other Current Assets7.1 M12.7 M6.3 M
Slightly volatile
Other Stockholder Equity720.6 M686.3 M273.3 M
Slightly volatile
Short Term Debt25.9 M24.7 M5.4 M
Slightly volatile
Current Deferred Revenue13.6 M12.9 MM
Slightly volatile
Intangible Assets373.7 M355.9 M82.7 M
Slightly volatile
Long Term Debt666.3 M634.6 M109.9 M
Slightly volatile
Capital Lease Obligations6.7 M12.2 MM
Slightly volatile
Net Invested Capital1.4 B1.3 B290.6 M
Slightly volatile
Property Plant And Equipment Gross76.8 M73.2 M20.3 M
Slightly volatile
Short and Long Term Debt22.9 M21.8 MM
Slightly volatile
Non Current Liabilities Other23.3 M27.4 M45.3 M
Slightly volatile
Net Working Capital709.6 M675.8 M173.4 M
Slightly volatile
Long Term Investments7.3 M5.5 M11.2 M
Slightly volatile

Telix Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses846.6 M806.2 M199.6 M
Slightly volatile
Depreciation And Amortization3.7 M6.5 M3.6 M
Slightly volatile
Interest Expense25.9 M24.7 M5.6 M
Slightly volatile
Selling General Administrative146.9 M139.9 M38.5 M
Slightly volatile
Total Revenue945.7 M900.7 M207 M
Slightly volatile
Cost Of Revenue330.3 M314.6 M88.9 M
Slightly volatile
Research Development146.1 M139.2 M40.8 M
Slightly volatile
Selling And Marketing Expenses103.2 M98.3 M22.9 M
Slightly volatile
Interest Income13.1 M12.5 M2.2 M
Slightly volatile
Reconciled Depreciation6.1 M7.8 M5.4 M
Slightly volatile

Telix Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
DepreciationMM4.2 M
Slightly volatile
Capital Expenditures41.1 M39.1 M8.5 M
Slightly volatile
End Period Cash Flow857.7 M816.9 M167.5 M
Slightly volatile
Stock Based Compensation10.6 M10.1 M3.1 M
Slightly volatile
Dividends Paid43.8 M49.3 M53.8 M
Slightly volatile
Issuance Of Capital Stock854.1 K899.1 K34.2 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.3711.97394
Slightly volatile
Dividend Yield0.530.590.647
Slightly volatile
PTB Ratio12.2712.9166.9355
Pretty Stable
Days Sales Outstanding80.9585.219.1 K
Slightly volatile
Book Value Per Share1.621.540.5532
Slightly volatile
Stock Based Compensation To Revenue0.01910.02011.9971
Slightly volatile
Capex To Depreciation0.811.41.1971
Pretty Stable
PB Ratio12.2712.9166.9355
Pretty Stable
EV To Sales11.1911.78327
Slightly volatile
Inventory Turnover7.838.258.9436
Slightly volatile
Days Of Inventory On Hand55.6158.5313.5 K
Slightly volatile
Payables Turnover3.053.582.0936
Slightly volatile
Sales General And Administrative To Revenue0.160.1723.7791
Slightly volatile
Average Inventory424.9 K533 K514.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.270.2951.6766
Slightly volatile
Capex To Revenue0.0960.050.1105
Slightly volatile
Cash Per Share2.031.930.6064
Slightly volatile
Days Payables Outstanding10010512.5 K
Slightly volatile
Intangibles To Total Assets0.270.250.2041
Slightly volatile
Current Ratio3.033.1916.0679
Slightly volatile
Receivables Turnover4.664.431.4716
Slightly volatile
Graham Number1.132.170.6769
Slightly volatile
Shareholders Equity Per Share1.621.540.5533
Slightly volatile
Debt To Equity0.970.920.2638
Slightly volatile
Capex Per Share0.09710.09250.0224
Slightly volatile
Average Receivables8.8 M9.9 M10.8 M
Slightly volatile
Revenue Per Share2.232.130.5227
Slightly volatile
Interest Debt Per Share1.721.640.3145
Slightly volatile
Debt To Assets0.360.350.0772
Slightly volatile
Operating Cycle13714414.7 K
Slightly volatile
Price Book Value Ratio12.2712.9166.9355
Pretty Stable
Days Of Payables Outstanding10010512.5 K
Slightly volatile
Ebt Per Ebit1.020.781.0032
Pretty Stable
Company Equity Multiplier2.282.44.5475
Pretty Stable
Long Term Debt To Capitalization0.470.440.0965
Slightly volatile
Total Debt To Capitalization0.480.460.1383
Slightly volatile
Debt Equity Ratio0.970.920.2638
Slightly volatile
Quick Ratio2.913.0615.936
Slightly volatile
Net Income Per E B T0.770.80.902
Pretty Stable
Cash Ratio2.352.4715.4033
Slightly volatile
Cash Conversion Cycle36.4138.322.1 K
Pretty Stable
Days Of Inventory Outstanding55.6158.5313.5 K
Slightly volatile
Days Of Sales Outstanding80.9585.219.1 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.230.240.8441
Slightly volatile
Price To Book Ratio12.2712.9166.9355
Pretty Stable
Fixed Asset Turnover13.6312.984.5817
Slightly volatile
Debt Ratio0.360.350.0772
Slightly volatile
Price Sales Ratio11.3711.97394
Slightly volatile
Asset Turnover0.290.460.195
Slightly volatile
Price Fair Value12.2712.9166.9355
Pretty Stable

Telix Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap124.2 M118.2 M99.7 M
Slightly volatile
Enterprise Value101.4 M96.6 M71.7 M
Slightly volatile

Telix Fundamental Market Drivers

Forward Price Earnings66.6667
Cash And Short Term Investments710.3 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue12.9 M13.6 M
Total Revenue900.7 M945.7 M
Cost Of Revenue314.6 M330.3 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.17  0.16 
Research And Ddevelopement To Revenue 0.29  0.27 
Capex To Revenue 0.05  0.10 
Revenue Per Share 2.13  2.23 
Ebit Per Revenue 0.09  0.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.